Artículos con órdenes de acceso público - Antoni RibasMás información
No disponibles en ningún lugar: 11
Revisar
Melanoma
D Schadendorf, DE Fisher, C Garbe, JE Gershenwald, JJ Grob, A Halpern, ...
Nature reviews Disease primers 1 (1), 1-20, 2015
Órdenes: US National Institutes of Health
Revisar
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
DS Shin, A Ribas
Current opinion in immunology 33, 23-35, 2015
Órdenes: US National Institutes of Health
Revisar
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
A Ribas, R Gonzalez, A Pavlick, O Hamid, TF Gajewski, A Daud, ...
The lancet oncology 15 (9), 954-965, 2014
Órdenes: US National Institutes of Health, National Health and Medical Research …
Revisar
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio, V Atkinson, H Schmidt, ...
Nature medicine 25 (6), 941-946, 2019
Órdenes: US National Institutes of Health
Revisar
MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy
J Reinhardt, J Landsberg, JL Schmid-Burgk, BB Ramis, T Bald, N Glodde, ...
Cancer research 77 (17), 4697-4709, 2017
Órdenes: National Health and Medical Research Council, Australia, German Research …
Revisar
Targeting oncogenic drivers and the immune system in melanoma
GA McArthur, A Ribas
Journal of clinical oncology 31 (4), 499-506, 2013
Órdenes: National Health and Medical Research Council, Australia
Revisar
DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase III trial—ECOG-ACRIN EA6134.
MB Atkins, SJ Lee, B Chmielowski, A Ribas, AA Tarhini, TG Truong, ...
Journal of Clinical Oncology 39 (36_suppl), 356154-356154, 2021
Órdenes: US National Institutes of Health
Revisar
Anti–PD-1 therapy in melanoma
BH Moreno, G Parisi, L Robert, A Ribas
Seminars in oncology 42 (3), 466-473, 2015
Órdenes: US National Institutes of Health, V Foundation, USA
Revisar
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44
AL Cummings, J Gukasyan, HY Lu, T Grogan, G Sunga, CM Fares, ...
Nature cancer 1 (12), 1167-1175, 2020
Órdenes: US National Institutes of Health
Revisar
Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma
S Ray, A Chhabra, S Mehrotra, NG Chakraborty, A Ribas, J Economou, ...
Clinics in dermatology 27 (6), 603-613, 2009
Órdenes: US National Institutes of Health
Revisar
Which therapy for which patient?
A Ribas
Future Medicine Ltd, 2011
Órdenes: US National Institutes of Health
Disponibles en algún lugar: 304
Revisar
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
Órdenes: US National Institutes of Health
Revisar
PD-1 blockade induces responses by inhibiting adaptive immune resistance
PC Tumeh, CL Harview, JH Yearley, IP Shintaku, EJM Taylor, L Robert, ...
Nature 515 (7528), 568-571, 2014
Órdenes: US National Institutes of Health, Howard Hughes Medical Institute, V …
Revisar
Cancer immunotherapy using checkpoint blockade
A Ribas, JD Wolchok
Science 359 (6382), 1350-1355, 2018
Órdenes: US National Institutes of Health
Revisar
Primary, adaptive, and acquired resistance to cancer immunotherapy
P Sharma, S Hu-Lieskovan, JA Wargo, A Ribas
Cell 168 (4), 707-723, 2017
Órdenes: US National Institutes of Health
Revisar
Genetic basis for clinical response to CTLA-4 blockade in melanoma
A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ...
New England Journal of Medicine 371 (23), 2189-2199, 2014
Órdenes: US National Institutes of Health
Revisar
Inhibition of mutated, activated BRAF in metastatic melanoma
KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ...
New England Journal of Medicine 363 (9), 809-819, 2010
Órdenes: US National Institutes of Health
Revisar
Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ...
New England Journal of Medicine 369 (2), 134-144, 2013
Órdenes: US National Institutes of Health
Revisar
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ...
Cell 165 (1), 35-44, 2016
Órdenes: US National Institutes of Health
Revisar
Mutations associated with acquired resistance to PD-1 blockade in melanoma
JM Zaretsky, A Garcia-Diaz, DS Shin, H Escuin-Ordinas, W Hugo, ...
New England Journal of Medicine 375 (9), 819-829, 2016
Órdenes: US National Institutes of Health
La información de publicación y financiación se determina de forma automática mediante un programa informático